Showing 221-225 of 313 resources:
Leveraging “Re-Usable” Data Networks for Prospective Research and Post Marketing Commitments

Wed, Aug 18, 2021 2:00 PM – 3:00 PM EDT Presenter: Richard Gliklich, MD, CEO, OM1 Register >> Automated, clinical ‘data networks’ are transforming the research paradigm. This webinar explores: – How do multi-purpose, ‘reusable’ data networks differ from the traditional research model, in particular for real-world evidence and patient registries? – How are data[…]

Real-World Data & Technology Company OM1 Closes $85 Million Financing To Make Healthcare More Measured, Precise, And Pre-Emptive

BOSTON, July 16, 2021 /PRNewswire/ — OM1, a health technology company focused on real-world outcomes for chronic conditions, today announced an $85 million financing led by D1 Capital Partners, Kaiser Permanente, and Breyer Capital, with participation from existing investors, including General Catalyst (GC), Polaris Partners, Scale Venture Partners, 7wire Ventures, and Glikvest. OM1 partners with providers, medical societies, payers, and[…]

Dell Medical School helps develop artificial intelligence tool for knee surgery

April 2, 2021 – Austin American-Statesman Read the Full Article >> If you had osteoarthritis in your knee, how would you know when it’s the right time to have knee replacement surgery? Dell Medical School at the University of Texas helped patients at UT Health Austin’s Musculoskeletal Institute answer that question by studying a new artificial intelligence tool[…]

Validation Of A Machine Learning Approach To Estimate Systemic Lupus Erythematosus Disease Activity Index Score Categories And Application In A Real-World Dataset

BMJ Journals Published: May 20, 2021 Read the Full Manuscript >>  Objective Use of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in routine clinical practice is inconsistent, and availability of clinician-recorded SLEDAI scores in real-world datasets is limited. This study aimed to validate a machine learning model to estimate SLEDAI score categories using clinical notes[…]

OM1 Launches Multiple Sclerosis Registry With More Than 20,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, July 14, 2021 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its multiple sclerosis (MS) registry. MS is an auto-immune, inflammatory disease that attacks the central nervous system (CNS) and causes a variety of neurological symptoms, such as muscle weakness, spasticity, fatigue, numbness, vision[…]